ArticleBMC cancer2024

Reply to "Matters arising: cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non-small cell lung cancer: a modelling approach".

Wen Hui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.